Blurbs

Analysts Are Bullish on These Healthcare Stocks: Puma Biotechnology (PBYI), Selecta Biosciences (SELB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Puma Biotechnology (PBYIResearch Report) and Selecta Biosciences (SELBResearch Report) with bullish sentiments.

Puma Biotechnology (PBYI)

H.C. Wainwright analyst Edward White reiterated a Buy rating on Puma Biotechnology yesterday and set a price target of $12.00. The company’s shares closed last Monday at $2.39, close to its 52-week low of $1.60.

According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -30.0% and a 19.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

Puma Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.

See today’s best-performing stocks on TipRanks >>

Selecta Biosciences (SELB)

In a report released yesterday, Joseph Schwartz from SVB Securities initiated coverage with a Buy rating on Selecta Biosciences and a price target of $7.00. The company’s shares closed last Monday at $1.00, close to its 52-week low of $0.65.

According to TipRanks.com, Schwartz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -15.5% and a 26.2% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Mereo Biopharma Group Plc, and Crinetics Pharmaceuticals.

Currently, the analyst consensus on Selecta Biosciences is a Strong Buy with an average price target of $7.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PBYI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed